Table 2.

Patients’ Characteristics

Factors	N
Sex
Male	7
Female	12
Age (y), median (range)	66 (42–84)
Smoking history
Positive	6
EGFR mutation before EGFR TKI
Del19	12
L858R	7
Median duration on osimertinib, mo (range)	18.5 (8.8–29.1)
TKI(s) before osimertinib
Gefitinib	13
Erlotinib	8
Afatinib	7
Received more than one TKI before osimertinib	8
Cumulative duration on TKI(s) before osimertinib	24.7 (7.6–46)

Del19, exon 19 deletion; TKI, tyrosine kinase inhibitor.